FreeCME

Hidradenitis Suppurativa (HS): Optimizing the Management Approach with Available and Emerging Treatments

This activity is provided by Physicians’ Education Resource®, LLC.


Acknowledgment of Commercial Support
This activity is supported by educational grants from AbbVie Inc and Novartis Pharmaceuticals.



Hidradenitis suppurativa (HS) is a chronic, immune-mediated, inflammatory skin disease associated with significant morbidity due to recurrence of disease flares, pain, malodorous drainage of abscesses, and comorbidities. Early intervention is important, but there is evidence indicating that diagnosis can be delayed for many years, during which time the majority of patients report multiple physician consultations before receiving an accurate diagnosis. This delayed or missed diagnosis often results in fragmented care and inappropriate treatments, which contribute to disease progression and morbidity. Treatment options for HS encompass both pharmacologic and nonpharmacologic interventions, but the limited availability of evidence supporting the use of available treatments has made it difficult to recommend a single treatment strategy. Furthermore, HS has proven to be a challenging condition that requires a comprehensive, multidisciplinary, individualized management approach. These educational resources contribute to the optimization of HS management by presenting the latest research, exploring the role of investigational agents for the treatment of HS, and discussing care strategies that enhance the patient experience and improve outcomes.

CE Activity Curriculum